Stock 000504 LANDFAR BIO-MEDICINE CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Landfar Bio-medicine Co., Ltd Share Price

Equities

000504

CNE000000263

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
6.93 CNY +1.32% Intraday chart for Landfar Bio-medicine Co., Ltd +0.43% -40.26%
04-11 Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million. CI
2023 Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Financials

Sales 2021 157M 21.61M 1.73B Sales 2022 200M 27.65M 2.21B Capitalization 3.63B 501M 40.08B
Net income 2021 -19M -2.62M -210M Net income 2022 -12M -1.66M -133M EV / Sales 2021 38 x
Net Debt 2021 154M 21.29M 1.71B Net Debt 2022 16.5M 2.28M 182M EV / Sales 2022 18.2 x
P/E ratio 2021
-310 x
P/E ratio 2022
-291 x
Employees 512
Yield 2021 *
-
Yield 2022
-
Free-Float 51.63%
More Fundamentals * Assessed data

Chart Landfar Bio-medicine Co., Ltd

Dynamic Chart

Latest news about Landfar Bio-medicine Co., Ltd

Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million. CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Landfar Bio Medicine’s Controlling Shareholder Boosts Stake to 30% MT
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Landfar Bio-medicine Co., Ltd completed the acquisition of additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. for CNY 9.7 million. CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
NanHua Bio-medicine Co., Ltd announced that it expects to receive CNY 275.999987 million in funding from Hunan Chasing Fund Management Co., Ltd. CI
NanHua Bio-medicine Co., Ltd signed a letter of intent to acquire Medicine-related assets from YanAn Bicon Pharmaceutical Listed Company. CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news

Quotes and Performance

1 day+1.32%
1 week+0.43%
Current month-19.88%
1 month-22.31%
3 months-30.21%
6 months-37.45%
Current year-40.26%
More quotes

Highs and lows

1 week
6.53
Extreme 6.53
6.97
1 month
6.25
Extreme 6.25
8.76
Current year
5.26
Extreme 5.26
12.18
1 year
5.26
Extreme 5.26
13.17
3 years
5.26
Extreme 5.26
24.97
5 years
5.26
Extreme 5.26
24.97
10 years
5.26
Extreme 5.26
36.97
More quotes

Managers and Directors - Landfar Bio-medicine Co., Ltd

Managers TitleAgeSince
Chang Qiao You CEO
 Chief Executive Officer 51 16/06/20
Peng Bin Lin DFI
 Director of Finance/CFO 51 26/01/15
Zhi Fu Li IRC
 Investor Relations Contact - -
Members of the board TitleAgeSince
Chang Qiao You CEO
 Chief Executive Officer 51 16/06/20
Ping Zhao BRD
 Director/Board Member 53 28/12/21
Yuan Chen BRD
 Director/Board Member 43 29/11/17
More insiders

Quotes

Date Price Change Volume
26/04/24 6.93 +1.32% 2,294,200
25/04/24 6.84 +1.63% 2,284,700
24/04/24 6.73 +0.60% 2,218,330
23/04/24 6.69 +1.98% 3,850,802
22/04/24 6.56 -4.93% 4,508,500

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes

Company Profile

Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Company’s biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Company’s energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.
Sector
Healthcare Facilities & Services
Calendar
29/04/2024 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
LANDFAR BIO-MEDICINE CO., LTD Stock Landfar Bio-medicine Co., Ltd
-40.26% 316M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-17.89% 8.25B
RADNET, INC. Stock RadNet, Inc.
+39.20% 3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-39.11% 2.46B
SYNLAB AG Stock SYNLAB AG
-8.06% 2.46B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-7.35% 2.38B
FLEURY S.A. Stock Fleury S.A.
-19.01% 1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.66% 1.21B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+7.56% 1.11B
ADICON HOLDINGS LIMITED Stock Adicon Holdings Limited
-15.34% 1.03B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. 000504 Stock